Intensity Therapeutics Inc banner

Intensity Therapeutics Inc
R&D

R&D · Sep 2026 report

R&D declined in the latest quarter

-$2.4m
-32.5%
-$6.8m
+35.4%
-$7m
+4% YoY

Quarterly R&D reached -$2.4m, down 56.4% year over year and down 32.5% sequentially; LTM R&D was -$7m, down 14.4% from the preceding LTM observation of -$6.1m.

Growth

Horizon Past Forecast Difference
Quarter N/A N/A
1 year N/A N/A
3-year CAGR N/A N/A
5-year CAGR N/A N/A
10-year CAGR N/A N/A N/A

No analyst forecasts are available for R&D.

History

Statistic Value Reporting period
Average value -$6.4m Dec 2020 – Dec 2025
Median value -$5.5m Dec 2020 – Dec 2025
Highest value -$4.8m Dec 2023
Lowest value -$10.5m Dec 2024
Largest annual decline -$5.7m (-119.3%) Dec 2023 – Dec 2024

Intensity Therapeutics Inc
R&D Peer Comparison

Intensity Therapeutics Inc
Income Statement

USD
Metric FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
0 0 0 0 0 0
(6.2m) (8m) (7.6m) (8.3m) (16.6m) (12m)
(1.2m) (2.2m) (2.4m) (3.5m) (6.1m) (5.2m)
R&D
(5.1m) (5.9m) (5.1m) (4.8m) (10.5m) (6.8m)
(6.2m) (8m) (7.6m) (8.3m) (16.6m) (12m)
74k 2.6k (80k) 19k 314k 180k
— — 82k 305k — —
— — 0 (2.3m) 0 —
118.8k 115.5k 48k 24k 3k 186k
(6m) (7.9m) (7.6m) (10.5m) (16.3m) (11.6m)
— — — — 0 —
(6m) (7.9m) (7.6m) (10.5m) (16.3m) (11.6m)
(6m) (7.9m) (7.6m) (11.9m) (16.3m) (11.6m)
(11.50) (15.06) (14.47) (21.63) (29.24) (8.56)

Intensity Therapeutics Inc
Glance View

Market Cap
9.1m USD
Industry
Biotechnology

Intensity Therapeutics is a clinical-stage biotechnology company that develops cancer treatments designed to be injected directly into a tumor. Its approach uses the tumor itself to help trigger an immune response, with the goal of shrinking the injected tumor and helping the body attack cancer elsewhere. The company’s lead work is focused on solid tumors, where doctors and cancer centers would be the users if the therapies reach market. The company does not sell approved drugs yet, so it does not have a traditional commercial customer base. Today it funds its work through equity financing and, if it signs them, research or licensing partnerships with larger drug companies. If its treatments are approved in the future, it would likely make money from product sales, licensing fees, and possible royalties. What makes Intensity Therapeutics different is that it is trying to turn a tumor into part of the treatment process instead of relying only on medicines that circulate through the whole body. That could fit alongside surgery, radiation, and other cancer drugs, and it gives the company a shot at becoming a specialty oncology developer focused on local tumor treatment rather than a broad drug maker.

INTS Intrinsic Value

Create a free account · No card needed

What is Intensity Therapeutics Inc's R&D?
R&D
-6.8m USD

Based on the financial report for Dec 31, 2025, Intensity Therapeutics Inc's R&D amounts to -6.8m USD.

What is Intensity Therapeutics Inc's R&D growth rate?
R&D CAGR 5Y
-6%

Over the last year, the R&D growth was 35%. The average annual R&D growth rates for Intensity Therapeutics Inc have been -10% over the past three years , -6% over the past five years .

Back to Top